Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald started coverage on shares of Replimune Group (NASDAQ:REPL - Get Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage set an "overweight" rating on the stock.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler raised their price target on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday, June 2nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Replimune Group presently has an average rating of "Buy" and a consensus target price of $20.83.

Replimune Group Price Performance

Shares of REPL opened at $9.49 on Friday. The company has a 50 day moving average of $8.80 and a two-hundred day moving average of $10.82. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17. Replimune Group has a twelve month low of $6.44 and a twelve month high of $17.00. The company has a market cap of $731.58 million, a price-to-earnings ratio of -3.09 and a beta of 0.63.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the business earned ($0.25) earnings per share. As a group, analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 7,952 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares of the company's stock, valued at $1,184,279.98. The trade was a 5.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Philip Astley-Sparke sold 32,279 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the sale, the director now owns 1,405,071 shares in the company, valued at $11,324,872.26. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock worth $603,655 over the last quarter. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares during the period. US Bancorp DE boosted its holdings in Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after buying an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd grew its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Replimune Group by 897.2% in the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock valued at $902,000 after buying an additional 7,913 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.